Several other weight-loss pills are also in late-stage trials ... of safety and that we will continue to see the benefits that we’ve seen already with semaglutide, potentially even on a grander scale, ...
Ongoing shortages of popular weight loss and diabetes drugs in the U.S. have spurred fierce competition between established drugmakers and an emerging market of compounded versions as telehealth ...
The future of oral weight loss medication looks bright. Drug manufacturer Novo Nordisk announced a new experimental ...
People who take Novo Nordisk's semaglutide-based injectables Ozempic and Wegovy seem to be way less likely to die from ...
Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.
Semaglutide, the underlying drug marketed as Ozempic and Wegovy, works by mimicking a hormone that triggers the body to feel ...
People with a history of opioid abuse who took Novo Nordisk A/S’s Ozempic were less likely to overdose, according to a study that adds to a growing body of evidence suggesting it may help manage ...
Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.
Compounded semaglutide is not a generic alternative to these drugs ... This may be because they’re allergic to a dye in the ...
6d
The results of Novo Nordisk’s phase 1 trials shows the oral weight loss pill could be more effective than semaglutide.
Is Novo Nordisk helping Americans save taxpayer money or ripping them off? The company’s CEO is scheduled to testify Tuesday on Capitol Hill.
In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback